HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 8, August 2016 – Novel Technologies for Antibody Drug Discovery in Japan       » Global Experts Convene to Discuss China's Plan for Diabetes Prevention and Rehabilitation in 2016       » Butterflies Offer Climate Scientists Ecological Insights       » Thermal Stability of Camelid Single Domain VHH Antibody       » That Gut Feeling: How A Healthy Digestive System Has Everything To Do With It       » World Heart Day - At the Heart of Health      
BIOBOARD - INSIDE INDUSTRY
Otsuka acquires rights to hematological cancer treatment Dacogen® from Eisai
Otsuka Pharmaceutical has entered an agreement with Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. to acquire rights to the hematological cancer treatment Dacogen® and to an enzyme inhibitor, E7727.

Eisai will receive the following rights from Otsuka.

  1. Exclusive rights to the development and sale of DNA methylation inhibitor Dacogen®, an intravenous formulation of decitabine (generic name), in the U.S., Canada, and Japan in addition to the licensing rights worldwide excluding Mexico. Eisai will retain the rights in Mexico. Janssen Pharmaceutical Companies will retain its worldwide development and commercialization rights (excluding the U.S., Canada, Mexico and Japan).

  2. Patent rights to metabolic enzyme inhibitor E7727, currently in pre-clinical development by Otsuka's U.S. subsidiary Astex Pharmaceuticals, Inc. E7727 is in development together with decitabine to form the combination product ASTX727 (an oral hypomethylating agent), which if approved would become the first oral formulation of decitabine.
Source: Business Wire

Click here for the complete issue.

NEWS CRUNCH  
news CPhI's Pre-Connect Congress outlines current trends in pharma
news World Population Day 2016
news NUS Student Clinches Top Prize at National Smart Mapping Competition with Cutting-Edge Food Security Solution
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Big Data in Healthcare
December:
Evidence-based TCM
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy